MedTrace Logo

BCMA-CD19 CAR-T Therapy for Refractory Autoimmune Diseases

NCT06794008 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2025-04-02

No results posted yet for this study

Summary

The objective of this study is to evaluate the efficacy and safety of BCMA/CD19 chimeric antigen receptor (CAR)-modified T cells in the treatment of autoimmune diseases.

Conditions

  • Systemic Lupus Erythematosus
  • Inflammatory Myopathy
  • Systemic Sclerosis (SSc)
  • ANCA-associated Vasculitis
  • IgG4-Related Diseases
  • Antiphospholipid Syndrome
  • Acquired Thrombotic Thrombocytopenic Purpura
  • Behcet Disease
  • Sjogren Syndrome

Interventions

DRUG

BCMA-CD19 CAR-T therapy

Patients received the BCMA-CD19-targeted CAR-T cells with a dosage of 3×10\^6/kg CAR-T cells per kilogram.

Sponsors & Collaborators

  • Peking University People's Hospital

    lead OTHER

Principal Investigators

  • Zhanguo Li · Peking University Institute of Rheuamotology and Immunology

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-12-26
Primary Completion
2027-12-30
Completion
2027-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06794008 on ClinicalTrials.gov